Femasys announces peer-reviewed data from FemaSeed ITI in JGRM

Femasys (FEMY) announces the peer-reviewed publication of positive data from its pivotal trial of FemaSeed intratubal insemination, ITI, in the Journal of Gynecology & Reproductive Medicine, JGRM, a leading peer-reviewed journal covering gynecology and reproductive medicine. “We are grateful for the renowned investigators from leading academic medical centers and private practices that participated in this landmark trial,” stated Kathy Lee-Sepsick, CEO of Femasys. “Our impressive pivotal data for FemaSeed, showed significantly improved pregnancy rates, over double that of intrauterine insemination for low male sperm count, a primary or contributing cause of infertility for approximately 50% of couples. FemaSeed offers a highly effective, first-line solution for women and couples seeking a less invasive and more affordable option than in vitro fertilization.”